Anti-Asialo GM1 NK Cell Depleting Antibody Does Not Alter the Development of Bleomycin Induced Pulmonary Fibrosis

Despite circumstantial evidence postulating a protective role for NK cells in many fibrotic conditions, their contribution to the development of pulmonary fibrosis has yet to be tested. Lung-migrating NK cells are thought to attenuate the development of bleomycin induced pulmonary fibrosis (BIPF) by providing anti-fibrotic mediators and cytokines, such as IFN-γ. If true, we reasoned that depletion of NK cells during experimentally-induced fibrotic disease would lead to exacerbated fibrosis. To test this, we treated mice with NK cell-depleting antisera (anti-asialo GM1) and evaluated lung inflammation and fibrosis in the BIPF model. While NK cell infiltration into the airways was maximal at day 10 after bleomycin injection, NK cells represented a minor portion (1–3%) of the total leukocytes in BAL fluid. Anti-asialo GM1 significantly abrogated NK cell numbers over the course of the disease. Depletion of NK cells with anti-asialo GM1 before and throughout the BIPF model, or during just the fibrotic phase did not alter fibrosis development or affect the levels of any of the pro-inflammatory/pro-fibrotic cytokines measured (IL-1β, IL-17, IFN-γ, TGF-β and TNF-α). In addition, adoptively transferred NK cells, which were detectable systemically and in the airways throughout BIPF, failed to impact lung fibrosis. These findings indicate that NK cells likely do not play an essential protective role in controlling pulmonary fibrosis development.

[1]  R. Welsh,et al.  Therapeutic Depletion of Natural Killer Cells Controls Persistent Infection , 2013, Journal of Virology.

[2]  Lianfeng Zhang,et al.  Transgenic expression of IL-33 activates CD8(+) T cells and NK cells and inhibits tumor growth and metastasis in mice. , 2013, Cancer letters.

[3]  Z. Tian,et al.  Natural killer cells in liver disease , 2013, Hepatology.

[4]  K. Kane,et al.  NK cells exacerbate the pathology of influenza virus infection in mice , 2013, European journal of immunology.

[5]  W. Ouyang,et al.  IL-22 from conventional NK cells is epithelial regenerative and inflammation protective during influenza infection , 2012, Mucosal Immunology.

[6]  J. Ledford,et al.  Surfactant protein-D regulates effector cell function and fibrotic lung remodeling in response to bleomycin injury. , 2012, American journal of respiratory and critical care medicine.

[7]  C. Trautwein,et al.  The chemokine receptor CXCR3 limits injury after acute toxic liver damage , 2012, Laboratory Investigation.

[8]  K. Schwarz,et al.  Subtle differences in CTL cytotoxicity determine susceptibility to hemophagocytic lymphohistiocytosis in mice and humans with Chediak-Higashi syndrome. , 2011, Blood.

[9]  Thomas A. Wynn,et al.  Integrating mechanisms of pulmonary fibrosis , 2011, The Journal of experimental medicine.

[10]  H. Karasuyama,et al.  NK Cell-Depleting Anti-Asialo GM1 Antibody Exhibits a Lethal Off-Target Effect on Basophils In Vivo , 2011, The Journal of Immunology.

[11]  M. Gunn,et al.  Recruited exudative macrophages selectively produce CXCL10 after noninfectious lung injury. , 2011, American journal of respiratory cell and molecular biology.

[12]  E. Casanova,et al.  A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development. , 2011, Blood.

[13]  R. Homer,et al.  Inhibition of pulmonary fibrosis in mice by CXCL10 requires glycosaminoglycan binding and syndecan-4. , 2010, The Journal of clinical investigation.

[14]  T. Wynn,et al.  Bleomycin and IL-1β–mediated pulmonary fibrosis is IL-17A dependent , 2010, The Journal of experimental medicine.

[15]  M. Jordana,et al.  Influenza Infection Leads to Increased Susceptibility to Subsequent Bacterial Superinfection by Impairing NK Cell Responses in the Lung , 2010, The Journal of Immunology.

[16]  F. Culley Natural killer cells in infection and inflammation of the lung , 2009, Immunology.

[17]  B. Gao,et al.  Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases , 2009, Journal of leukocyte biology.

[18]  S. Sahn,et al.  Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial , 2009, The Lancet.

[19]  C. Hogaboam,et al.  Murine models of pulmonary fibrosis. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[20]  M. Fujimoto,et al.  E- and P-selectins synergistically inhibit bleomycin-induced pulmonary fibrosis. , 2006, The American journal of pathology.

[21]  S. Friedman,et al.  Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. , 2006, Journal of hepatology.

[22]  R. Sun,et al.  Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. , 2006, Gastroenterology.

[23]  W. Park,et al.  Natural killer T (NKT) cells attenuate bleomycin-induced pulmonary fibrosis by producing interferon-gamma. , 2005, The American journal of pathology.

[24]  M. Burdick,et al.  CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. , 2005, American journal of respiratory and critical care medicine.

[25]  W. Park,et al.  Natural killer T (NKT) cells attenuate bleomycin-induced pulmonary fibrosis by producing interferon-gamma. , 2005, The American journal of pathology.

[26]  A. Tominaga,et al.  Antitumor activity of eosinophils activated by IL-5 and eotaxin against hepatocellular carcinoma. , 2004, DNA and cell biology.

[27]  R. Homer,et al.  Regulation of pulmonary fibrosis by chemokine receptor CXCR3. , 2004, The Journal of clinical investigation.

[28]  Hideo Sakamoto,et al.  Inhibition of pulmonary fibrosis by the chemokine IP-10/CXCL10. , 2004, American journal of respiratory cell and molecular biology.

[29]  G. Izbicki,et al.  Role of interferon-γ in the evolution of murine bleomycin lung fibrosis , 2003 .

[30]  G. Izbicki,et al.  Role of interferon-gamma in the evolution of murine bleomycin lung fibrosis. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[31]  K. Koyama NK1.1+ cell depletion in vivo fails to prevent protection against infection with the murine nematode parasite Trichuris muris , 2002, Parasite immunology.

[32]  M. Zöller,et al.  Donor T cell and host NK depletion improve the therapeutic efficacy of allogeneic bone marrow cell reconstitution in the nonmyeloablatively conditioned tumor‐bearing host , 2002, Journal of leukocyte biology.

[33]  A. Pardo,et al.  Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy , 2001, Annals of Internal Medicine.

[34]  M. Wills-Karp,et al.  Attenuation of lung inflammation and fibrosis in interferon-gamma-deficient mice after intratracheal bleomycin. , 2001, American journal of respiratory cell and molecular biology.

[35]  J. Whitton,et al.  NK Markers Are Expressed on a High Percentage of Virus-Specific CD8+ and CD4+ T Cells1 , 2000, The Journal of Immunology.

[36]  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). , 2000, American journal of respiratory and critical care medicine.

[37]  David A. Lynch,et al.  Idiopathic pulmonary fibrosis: Diagnosis and treatment: International Consensus Statement , 2000 .

[38]  C. Larsen,et al.  Asialo GM1(+) CD8(+) T cells play a critical role in costimulation blockade-resistant allograft rejection. , 1999, The Journal of clinical investigation.

[39]  J M Simpson,et al.  Simple method of estimating severity of pulmonary fibrosis on a numerical scale. , 1988, Journal of clinical pathology.

[40]  R. Crystal,et al.  Familial idiopathic pulmonary fibrosis. Evidence of lung inflammation in unaffected family members. , 1986, The New England journal of medicine.

[41]  J Stein-Streilein,et al.  In vivo treatment of mice and hamsters with antibodies to asialo GM1 increases morbidity and mortality to pulmonary influenza infection. , 1986, Journal of immunology.

[42]  A. Santoni,et al.  Reactivity of Anti‐Asialo GM1 Serum With Tumoricidal and Non‐Tumoricidal Mouse Macrophages , 1985, Journal of leukocyte biology.

[43]  M. Kasai,et al.  A glycolipid on the surface of mouse natural killer cells , 1980, European journal of immunology.